Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
New data from Eli Lilly and Company (NYSE:LLY) showed Omvoh-treated patients with moderately to severely active ulcerative coli...
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Ol...
Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.
Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price cut...
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areat...
New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) wi...
